Liso-Cel Produces Deep, Durable Responses in Patients with H

Treatment with lisocabtagene maraleucel led to strong and durable response rates with little serious adverse effects in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma.

Related Keywords

Houston , Texas , United States , France , Michael Wong , Bristol Meyers Squibb , Franck Morschhauser , Department Of Lymphoma , Hematology At Centre Hospitalier Universitaire De Lille , International Conference On Malignant Lymphoma , Division Of Cancer Medicine , Transcend , University Of Texas Md Anderson Cancer Center , Centre Hospitalier Universitaire De Lille , Groupe De Recherche , Technologies Associ , Cancer Medicine , Cancer Center , Malignant Lymphoma ,